Literature DB >> 31554672

Fatal PCR-negative herpes simplex virus-1 encephalitis with GABAA receptor antibodies.

Simon Schuster1, Ligia Abrante2, Jakob Matschke2, Marc Lütgehetmann2, Brigitte Holst2, Mathias Gelderblom2, Hanna Braass2, Frank Leypoldt2, Tim Magnus2.   

Abstract

Entities:  

Year:  2019        PMID: 31554672      PMCID: PMC6807661          DOI: 10.1212/NXI.0000000000000624

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
Herpes simplex virus-1 encephalitis (HSVE) is the most common cause of fatal sporadic encephalitis worldwide. Recently, post-HSVE relapses due to autoimmune encephalitis with NMDA receptor antibodies and other synaptic autoantibodies have been reported in up to 27% of patients within 1–2 months after HSVE.[1,2] We report an unusual case of a patient with refractory status epilepticus due to HSVE with antibodies against GABAA receptors (GABAAR).

Case report

A 47-year-old man was admitted with a new-onset generalized seizure. Two days before admission, behavioral changes were observed. No psychiatric symptoms, headaches, or feverish infections had occurred in the previous weeks. He had a B-cell non-Hodgkin lymphoma 5 years ago and a Hodgkin lymphoma 16 years ago, both in complete remission after radiochemotherapy. Eventually, focal status epilepticus developed provoking intensified anticonvulsive treatment. Initial brain MRI showed hyperintense fluid-attenuated inversion recovery (FLAIR) signal of the left prefrontal gyrus without diffusion restriction (figure 1, A and D) or contrast enhancement. CSF analysis on the day of admission revealed lymphocytic pleocytosis (13 leukocytes/μL), elevated protein (574 mg/L), and lactate (2.74 mmol/L). IV acyclovir 750 mg TID was started. CSF herpes simplex virus-1 (HSV-1) quantitative polymerase chain reaction (qPCR) was negative. A second lumbar puncture (day 5 of admission) showed 29 lymphocytes/μL, normal protein, and slightly elevated lactate (2.27 mmol/L). HSV-1 DNA remained undetectable. Immunoglobulin G-HSV antibody index was unremarkable (<1.3); further analysis revealed no other infectious causes. However, GABAAR antibodies were detected in serum (1:1,600) and CSF (1:32) of the second lumbar puncture using cell-based assays, tissue-based assays, and life embryonal hippocampal neuron cultures (figure 1, G–I)[3]; no other neuronal antibodies were identified.
Figure

MRI findings and laboratory studies

MRI 1st day of admission (A and D) and 14 days after admission (B, C, E, and F), showing progression of the left frontal hyperintense lesion and new diffusion restriction left frontally and bilaterally in the operculum on day 14. (A–C) Axial fluid-attenuated inversion recovery-weighted images with hyperintense lesion of the left prefrontal gyrus (A and B) and the operculum bilaterally (C). (D–F) Diffusion-weighted images and apparent diffusion coefficient images (small insets) without diffusion restriction (D) and marked diffusion restriction in the left prefrontal gyrus (E) and the operculum bilaterally (F). (G) Immunolabeling of sagittal rat brain sections with the patient's CSF antibodies showing a characteristic pattern. Patient and control CSF 1:4. Anti-human IgG (H + L). Human IgM and IgA did not show immunoreactivity. Scale bar 1 mm. (H) Detection of antibodies to the GABAA receptors (GABAAR) using HEK293 cell-based assay. Patient's but not control serum detects GABAAR. Human GABAAR subunits transfected into HEK293 cells and stained via life cell staining (serum 1:40). Green human IgG, red commercial GABAAR antibody. Scale bar 20 μm. (I) Patient's but not control serum detects neuronal surface antigens. Nonpermeabilized embryonic rat hippocampal neuron cultures DIV21 life cell stained with human IgG and nuclear counterstaining with DAPI (blue). Scale bar 20 μm. (J) Postmortem herpes simplex virus antigen staining of the patient's hippocampus. Scale bar 5 mm. DAPI = 4′,6-diamidino-2-phenylindole; IgG = immunoglobulin G.

MRI findings and laboratory studies

MRI 1st day of admission (A and D) and 14 days after admission (B, C, E, and F), showing progression of the left frontal hyperintense lesion and new diffusion restriction left frontally and bilaterally in the operculum on day 14. (A–C) Axial fluid-attenuated inversion recovery-weighted images with hyperintense lesion of the left prefrontal gyrus (A and B) and the operculum bilaterally (C). (D–F) Diffusion-weighted images and apparent diffusion coefficient images (small insets) without diffusion restriction (D) and marked diffusion restriction in the left prefrontal gyrus (E) and the operculum bilaterally (F). (G) Immunolabeling of sagittal rat brain sections with the patient's CSF antibodies showing a characteristic pattern. Patient and control CSF 1:4. Anti-human IgG (H + L). Human IgM and IgA did not show immunoreactivity. Scale bar 1 mm. (H) Detection of antibodies to the GABAA receptors (GABAAR) using HEK293 cell-based assay. Patient's but not control serum detects GABAAR. Human GABAAR subunits transfected into HEK293 cells and stained via life cell staining (serum 1:40). Green human IgG, red commercial GABAAR antibody. Scale bar 20 μm. (I) Patient's but not control serum detects neuronal surface antigens. Nonpermeabilized embryonic rat hippocampal neuron cultures DIV21 life cell stained with human IgG and nuclear counterstaining with DAPI (blue). Scale bar 20 μm. (J) Postmortem herpes simplex virus antigen staining of the patient's hippocampus. Scale bar 5 mm. DAPI = 4′,6-diamidino-2-phenylindole; IgG = immunoglobulin G. Acyclovir was stopped, yet IV methylprednisolone did not induce clinical improvement. Follow-up MRI showed expansion of the left frontal hyperintense FLAIR lesion with accompanied diffusion restriction and new bilateral opercular diffusion restrictions (figure 1, B, C, E, F). Refractory status epilepticus continued (EEG, figure e-1, links.lww.com/NXI/A145). The patient died of bowel ischemia due to thrombosis of the mesenteric artery. Postmortem revealed extensive HSVE with necrosis, inflammation, positive HSV antigen, and tissue PCR (figure 1J). No evidence of lymphoma was found.

Discussion

We describe an unusual case of CSF-qPCR-negative HSVE with concomitant GABAAR antibodies. We confirmed presence and specificity of GABAAR antibodies in serum and CSF with high titers, typical staining on rat brain immunohistochemistry and neuronal synapses of live neurons in vitro. Our patient was initially misdiagnosed with idiopathic GABAAR encephalitis owing to detection of GABAAR antibodies, 2 negative HSV-1 qPCR in CSF, and characteristic clinical presentation with severe encephalitis and refractory status epilepticus.[3,4] HSVE was only diagnosed postmortem by demonstration of widespread viral replication in brain tissue. Coincidental development of HSVE and GABAAR encephalitis is unlikely because of the low incidence of both diseases; rather breakdown of immunologic tolerance toward GABAAR likely provoked by virus-induced destruction of neurons would be a plausible explanation.[5] Previous post-HSVE autoimmune encephalitis cases predominantly had a biphasic course. However, development in contiguity with HSVE symptoms similar to our case has been described in adults,[1] and relapses have been observed as early as 7 days after HSVE in a 2-month-old boy.[5] Furthermore, a case of post-HSVE GABAAR encephalitis was recently described in a 15-month-old child occurring 8 weeks after herpes infection, and a second case occurred following HHV6 encephalitis.[4] We are not aware of a case of post-HSVE GABAAR encephalitis in an adult patient. However, because of the unavailability of initial CSF antibody testing, we cannot exclude the presence of “premorbid” GABAAR antibodies as a coincidental finding related to previous lymphoma. Although, the “premorbid” presence of high-titer CSF GABAAR antibodies without a history of seizures appears less plausible than our current hypothesis of continuous post-HSVE GABAAR encephalitis. Pathologic-proven HSVE without detectable HSV-1 DNA in CSF is another unusual feature and was rarely reported.[6,7] Hypothetical explanations could be early lumbar puncture and analysis under pretreatment with acyclovir. The previous lymphoma could have predisposed toward (1) the development of HSVE as has been noted in inborn errors of pattern-recognition pathways and (2) a breakdown of immune tolerance and consecutively development of systemic GABAAR antibodies predisposing to rapid development of CNS autoimmunity after HSVE. In summary, this single case illustrates the occurrence of GABAAR antibodies in PCR-negative HSVE in an immunosuppressed patient resulting in misdiagnosis of idiopathic GABAAR encephalitis. Key clinical points are (1) the difficulty of ruling out HSVE with qPCR and immunoglobulin G antibody index, (2) the occurrence of GABAAR antibodies in parallel to HSVE, and (3) the possibility of unusual clinical courses of HSVE and post-HSVE autoimmune encephalitis in patients with immune deficiencies.
  7 in total

1.  Herpes simplex virus encephalitis is a trigger of brain autoimmunity.

Authors:  Thaís Armangue; Frank Leypoldt; Ignacio Málaga; Miquel Raspall-Chaure; Itxaso Marti; Charles Nichter; John Pugh; Monica Vicente-Rasoamalala; Miguel Lafuente-Hidalgo; Alfons Macaya; Michael Ke; Maarten J Titulaer; Romana Höftberger; Heather Sheriff; Carol Glaser; Josep Dalmau
Journal:  Ann Neurol       Date:  2014-02-25       Impact factor: 10.422

2.  Investigations in GABAA receptor antibody-associated encephalitis.

Authors:  Marianna Spatola; Mar Petit-Pedrol; Mateus Mistieri Simabukuro; Thaís Armangue; Fernanda J Castro; Maria I Barcelo Artigues; Maria R Julià Benique; Leslie Benson; Mark Gorman; Ana Felipe; Ruben L Caparó Oblitas; Myrna R Rosenfeld; Francesc Graus; Josep Dalmau
Journal:  Neurology       Date:  2017-02-15       Impact factor: 9.910

3.  Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.

Authors:  Mar Petit-Pedrol; Thaís Armangue; Xiaoyu Peng; Luis Bataller; Tania Cellucci; Rebecca Davis; Lindsey McCracken; Eugenia Martinez-Hernandez; Warren P Mason; Michael C Kruer; David G Ritacco; Wolfgang Grisold; Brandon F Meaney; Carmen Alcalá; Peter Sillevis-Smitt; Maarten J Titulaer; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2014-01-22       Impact factor: 44.182

4.  Autoimmune post-herpes simplex encephalitis of adults and teenagers.

Authors:  Thaís Armangue; Germán Moris; Verónica Cantarín-Extremera; Carlos Enrique Conde; Kevin Rostasy; Maria Elena Erro; Juan Carlos Portilla-Cuenca; Eulàlia Turón-Viñas; Ignacio Málaga; Beatriz Muñoz-Cabello; Carmen Torres-Torres; Sara Llufriu; Luis González-Gutiérrez-Solana; Guillermo González; Ignacio Casado-Naranjo; Myrna Rosenfeld; Francesc Graus; Josep Dalmau
Journal:  Neurology       Date:  2015-10-21       Impact factor: 9.910

5.  Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.

Authors:  Thaís Armangue; Marianna Spatola; Alexandru Vlagea; Simone Mattozzi; Marc Cárceles-Cordon; Eloy Martinez-Heras; Sara Llufriu; Jordi Muchart; María Elena Erro; Laura Abraira; German Moris; Luis Monros-Giménez; Íñigo Corral-Corral; Carmen Montejo; Manuel Toledo; Luis Bataller; Gabriela Secondi; Helena Ariño; Eugenia Martínez-Hernández; Manel Juan; Maria Angeles Marcos; Laia Alsina; Albert Saiz; Myrna R Rosenfeld; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2018-07-23       Impact factor: 44.182

6.  Herpes simplex encephalitis with two false-negative cerebrospinal fluid PCR tests and review of negative PCR results in the clinical setting.

Authors:  Adam C Adler; Srinath Kadimi; Catherine Apaloo; Corina Marcu
Journal:  Case Rep Neurol       Date:  2011-08-04

7.  A Fatal Case of Herpes Simplex Encephalitis with Two False-Negative Polymerase Chain Reactions.

Authors:  Aldo A Mendez; Annaliese Bosco; Lama Abdel-Wahed; Kendra Palmer; Karra A Jones; Annie Killoran
Journal:  Case Rep Neurol       Date:  2018-08-29
  7 in total
  6 in total

1.  An Enigmatic Case of a Febrile Infant With Seizures.

Authors:  Bhavishya Devireddy; Whitney Kalin; Frederick Laningham; Fouzia Naeem
Journal:  Cureus       Date:  2022-06-04

2.  Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis.

Authors:  Simone M Brändle; Manuela Cerina; Susanne Weber; Kathrin Held; Amélie F Menke; Carmen Alcalá; David Gebert; Alexander M Herrmann; Hannah Pellkofer; Lisa Ann Gerdes; Stefan Bittner; Frank Leypoldt; Bianca Teegen; Lars Komorowski; Tania Kümpfel; Reinhard Hohlfeld; Sven G Meuth; Bonaventura Casanova; Nico Melzer; Eduardo Beltrán; Klaus Dornmair
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

3.  Polymerase Chain Reaction (PCR)-Negative Herpes Simplex Virus (HSV) Encephalitis in a 62-Year-Old Woman With p-ANCA Vasculitis.

Authors:  Ravi Rajmohan; Dina Khoury; Mari Perez-Rosendahl; Lilit Mnatsakanyan; Leonid Groysman
Journal:  Cureus       Date:  2022-01-21

4.  Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? - A case report.

Authors:  Klaus Berek; Ronny Beer; Astrid Grams; Raimund Helbok; Anna Lindner; Bettina Pfausler; Alois Schiefecker; Florian Deisenhammer; Harald Hegen
Journal:  BMC Neurol       Date:  2022-04-05       Impact factor: 2.474

5.  Relapse of Herpes Simplex Encephalitis by Epilepsy Surgery 35 Years after the First Infection: A Case Report and Literature Review.

Authors:  Yasushi Iimura; Hidenori Sugano; Tetsuya Ueda; Shimpei Matsuda; Kostadin Karagiozov; Taiji Tsunemi; Masashi Takanashi; Tomoyo Shimada; Shinsuke Maruyama; Hiroshi Otsubo
Journal:  NMC Case Rep J       Date:  2021-06-11

6.  Anti-γ-aminobutyric acid-A receptor encephalitis with refractory seizures and cognitive impairment in a young woman: A case report.

Authors:  Xue Yang; Bo Deng; Shengjun Wang; Xiaotang Wang; Lili Cao; Xiangjun Chen; Xiuhe Zhao
Journal:  Front Neurol       Date:  2022-08-29       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.